Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 7
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Sher LD, et al. Among authors: pandit abid n. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22. Chest. 2022. PMID: 35217003 Free article. Clinical Trial.
Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Geng B, et al. Among authors: pandit abid n. J Allergy Clin Immunol Pract. 2022 Mar;10(3):732-741. doi: 10.1016/j.jaip.2021.12.006. Epub 2021 Dec 22. J Allergy Clin Immunol Pract. 2022. PMID: 34954123 Free article.
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P, Menzies-Gow A, Peters AT, Kuna P, Rabe KF, Altincatal A, Soler X, Pandit-Abid N, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Berger P, et al. Among authors: pandit abid n. Ann Allergy Asthma Immunol. 2023 Feb;130(2):215-224. doi: 10.1016/j.anai.2022.11.006. Epub 2022 Nov 7. Ann Allergy Asthma Immunol. 2023. PMID: 36356712 Free article. Clinical Trial.
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.
Busse WW, Paggiaro P, Muñoz X, Casale TB, Castro M, Canonica GW, Douglass JA, Tohda Y, Daizadeh N, Ortiz B, Pandit-Abid N. Busse WW, et al. Among authors: pandit abid n. Eur Respir J. 2021 Oct 7;58(4):2004605. doi: 10.1183/13993003.04605-2020. Print 2021 Oct. Eur Respir J. 2021. PMID: 34326187 Free PMC article.
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.
Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, Deniz Y. Hanania NA, et al. Among authors: pandit abid n. Ann Allergy Asthma Immunol. 2023 Feb;130(2):206-214.e2. doi: 10.1016/j.anai.2022.10.018. Epub 2022 Nov 2. Ann Allergy Asthma Immunol. 2023. PMID: 36332763 Free article. Clinical Trial.
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma.
Sher LD, Passalacqua G, Taillé C, Cohn L, Daizadeh N, Pandit-Abid N, Soler X, Khodzhayev A, Jacob-Nara JA, Deniz Y, Rowe PJ, Nag A, Zhang Y. Sher LD, et al. Among authors: pandit abid n. Ann Allergy Asthma Immunol. 2023 Mar;130(3):298-304. doi: 10.1016/j.anai.2022.12.002. Epub 2022 Dec 9. Ann Allergy Asthma Immunol. 2023. PMID: 36509407 Free article.
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, Deniz Y. Rabe KF, et al. Among authors: pandit abid n. J Allergy Clin Immunol Pract. 2022 Nov;10(11):2916-2924.e4. doi: 10.1016/j.jaip.2022.06.036. Epub 2022 Aug 23. J Allergy Clin Immunol Pract. 2022. PMID: 36028446 Free article.
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose.
Domingo C, Rabe KF, Price D, Brusselle G, Wechsler ME, Xia C, Pandit-Abid N, Gall R, Rowe PJ, Deniz Y, Jacob-Nara JA, Radwan A. Domingo C, et al. Among authors: pandit abid n. ERJ Open Res. 2023 Nov 13;9(6):00056-2023. doi: 10.1183/23120541.00056-2023. eCollection 2023 Nov. ERJ Open Res. 2023. PMID: 38020559 Free PMC article.
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ. Corren J, et al. Among authors: pandit abid n. ERJ Open Res. 2023 Oct 16;9(5):00037-2023. doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37859672 Free PMC article.
14 results